EMBER-4

About this trial

The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy in participants with early breast cancer that is estrogen receptor positive (ER+) and human epidermal receptor 2 negative (HER2-). Participants must have already taken endocrine therapy for two to five years and must have a higher-than-average risk for their cancer to return. Study participation could last up to 10 years. Eligible patients will be randomly put into one of two treatment groups in this study:
Experimental Arm: Imlunestrant
Active Comparator Arm: Investigator’s Choice of Endocrine Therapy

Patient Profile

Patients (18 years and older) who have previously received 2 to 5 years of adjuvant endocrine therapy for ER+, HER2- early breast cancer and whose breast cancer has an increased risk of recurrence.

Where’s this trial being run?

Beacon Hospital, Beaumont Hospital, Bon Secours Cork, Cork University Hospital, Sligo University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Galway, and University Hospital Waterford

Can I join this study / trial?

The first step we recommend is to talk to your doctor or the cancer trials team at your hospital. You can find contact details for cancer trials research units in Ireland here.

It’s also a good idea to print this page and bring it with you to your appointment. It can help guide the conversation and remind you of what to ask. You may also want to talk to your family or friends about your options, as they can offer support as you make decisions.

For more detailed information

Click Here

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Questions

---

Summary Data

Name:	EMBER-4
Number:	24-07
Full Title:	EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence.

Principal Investigator:
Type:	Industry Sponsored
Sponsor:	Eli Lilly and Company
Recruitment Started:	Global: October 2022 Ireland:

Global Recruitment Target:	6000
Ireland Recruitment Target:	244